Clinical Trials Logo

Transplant Glomerulopathy clinical trials

View clinical trials related to Transplant Glomerulopathy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03380377 Completed - Clinical trials for Kidney Transplant; Complications

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

Start date: February 21, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Antibody mediated rejection (ABMR) is a unique, significant and often severe form of allograft rejection. This single center, phase I/II, open label single-arm exploratory study focuses on enrolling ten patients with biopsy proven chronic antibody medicated rejection and/or donor specific antibody present at time of biopsy. Patients who qualify will be receiving clazakizumab (anti-IL6 monoclonal antibody) monthly x six doses. A protocol biopsy will be performed at 6 months and if improvement is seen, patients will continue another six doses for up to 12 months. For those completing 12 doses, there will be a 12 month protocol biopsy. For those who only received six doses, the next and last study visit will be at 12 months from enrollment. Total study duration is 12 months.